Trial Profile

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of IW-6463 When Administered to Healthy Volunteers as Single Ascending Doses, as Multiple Ascending Doses, and Under Fed Versus Fasting Conditions

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zagociguat (Primary)
Indications Alzheimer's disease; Mitochondrial disorders; Schizophrenia
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Cyclerion Therapeutics; Ironwood Pharmaceuticals; Tisento Therapeutics

14 Oct 2020 Results published in Cyclerion Therapeutics Media Release.
11 Aug 2020 Status changed from recruiting to completed.
13 Jan 2020 According to a Cyclerion Therapeutics Media release, topline readout anticipated in mid-2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com